Autopsy report · NCT00639392

Phase 1 Study of Zoledronic Acid in Sickle Cell Disease

“Ended early due to inability to identify eligible subjects”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

Virginia Commonwealth University

Sponsor type

University, hospital or other

Conditions

Sickle Cell Disease

Interventions

Placebo; Zoledronic Acid

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women
  “Stopped enrolling subjects due to challenge of identifying eligible participants” (75% match in meaning)
• Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
  “Failure to enroll a suitable number of qualified subjects.” (72% match in meaning)
• Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
  “Lack of eligible subjects.” (72% match in meaning)
• Effect of Externally Implantable Tissue Expansion Device on Scar Length
  “Inability to recruit eligible subjects” (71% match in meaning)
• Insulin Resistance in Pulmonary Arterial Hypertension
  “difficulty in finding eligible subjects” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.